Merck & Co. (MRK) Financials: History & Chart

Merck & Co., Inc. (MRK)MRKMerck & Co., Inc.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Rahway, NJ

75,000 employees

www.merck.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert Davis

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	65.59B	16.29B	16.32B	17.18B	15.80B	15.62B	15.62B	16.66B	16.11B
Cost of Goods Sold	15.80B	2.94B	4.82B	4.19B	3.85B	3.88B	3.83B	4.08B	3.75B
Gross Profit	49.79B	13.34B	11.51B	12.99B	11.95B	11.73B	11.80B	12.58B	12.37B
Gross Profit Margin	75.9%	81.9%	70.5%	75.6%	75.7%	75.1%	75.5%	75.5%	76.8%
Total Operating Expenses	31.69B	15.23B	5.35B	5.53B	5.59B	5.02B	7.45B	8.59B	6.24B
Research & Development	22.15B	12.56B	2.50B	3.55B	3.54B	3.12B	4.58B	5.86B	3.50B
Selling, General & Administrative	9.54B	2.67B	2.85B	1.97B	2.05B	1.91B	2.69B	2.73B	2.74B
Operating Income (EBIT)	18.10B	-1.88B	6.16B	7.46B	6.36B	6.71B	4.35B	3.98B	6.13B
Operating Margin	27.6%	-11.6%	37.7%	43.4%	40.2%	43.0%	27.8%	23.9%	38.0%
Income Before Tax (EBT)	11.63B	-3.53B	3.42B	6.75B	5.00B	5.90B	4.17B	4.09B	6.01B
Interest Income	234.00M	N/A	69.00M	96.00M	69.00M	109.00M	146.00M	127.00M	69.00M
Interest Expense	1.04B	N/A	411.00M	327.00M	305.00M	313.00M	328.00M	330.00M	310.00M
Other Income/Expense	-6.47B	-1.65B	-2.74B	-718.00M	-1.36B	-807.00M	-178.00M	106.00M	-122.00M
Net Income	8.94B	-4.24B	2.96B	5.79B	4.43B	5.08B	3.74B	3.16B	5.46B
Income Tax Expense	2.70B	709.00M	458.00M	958.00M	571.00M	818.00M	426.00M	929.00M	545.00M
Net Profit Margin	13.6%	-26.0%	18.2%	33.7%	28.0%	32.5%	24.0%	19.0%	33.9%
EBITDA	24.20B	-372.00M	8.63B	8.54B	7.42B	7.81B	5.54B	5.17B	7.26B
EBITDA Margin	36.9%	-2.3%	52.8%	49.7%	46.9%	50.0%	35.5%	31.0%	45.1%
Depreciation & Amortization	6.11B	1.51B	2.47B	1.07B	1.06B	1.10B	1.20B	1.19B	1.13B
EPS Basic	3.56	-1.72	1.20	2.32	1.76	2.01	1.48	1.25	2.15
EPS Diluted	3.55	-1.72	1.19	2.32	1.76	2.01	1.48	1.24	2.14
Shares Outstanding	2.47B	2.47B	2.47B	2.50B	2.51B	2.52B	2.54B	2.54B	2.53B
Diluted Shares Outstanding	2.47B	2.47B	2.49B	2.50B	2.51B	2.53B	2.54B	2.54B	2.54B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	64.93B	64.17B	60.12B	59.28B	48.70B	41.52B	39.12B	42.29B
Cost of Goods Sold	18.20B	15.19B	16.13B	17.41B	13.63B	13.62B	12.02B	13.51B
Gross Profit	46.73B	48.98B	43.99B	41.87B	35.08B	27.90B	27.11B	28.79B
Gross Profit Margin	72.0%	76.3%	73.2%	70.6%	72.0%	67.2%	69.3%	68.1%
Total Operating Expenses	23.25B	28.75B	41.03B	23.59B	21.88B	22.35B	19.18B	19.85B
Research & Development	12.51B	17.94B	30.53B	13.55B	12.24B	13.40B	9.72B	9.75B
Selling, General & Administrative	10.73B	10.10B	9.88B	9.67B	9.40B	8.57B	9.46B	10.10B
Operating Income (EBIT)	23.49B	20.22B	2.95B	18.28B	13.20B	5.55B	7.93B	8.93B
Operating Margin	36.2%	31.5%	4.9%	30.8%	27.1%	13.4%	20.3%	21.1%
Income Before Tax (EBT)	21.07B	19.94B	1.89B	16.44B	13.88B	5.86B	7.17B	8.70B
Interest Income	343.00M	415.00M	365.00M	157.00M	36.00M	59.00M	274.00M	343.00M
Interest Expense	1.36B	1.27B	1.15B	962.00M	806.00M	831.00M	893.00M	772.00M
Other Income/Expense	-2.42B	-285.00M	-1.06B	-1.84B	680.00M	315.00M	-755.00M	-230.00M
Net Income	18.25B	17.12B	365.00M	14.52B	13.05B	7.07B	9.84B	6.22B
Income Tax Expense	2.80B	2.80B	1.51B	1.92B	1.52B	1.34B	1.56B	2.51B
Net Profit Margin	28.1%	26.7%	0.6%	24.5%	26.8%	17.0%	25.2%	14.7%
EBITDA	29.32B	24.72B	6.83B	22.19B	16.41B	9.03B	11.24B	13.45B
EBITDA Margin	45.2%	38.5%	11.4%	37.4%	33.7%	21.8%	28.7%	31.8%
Depreciation & Amortization	5.84B	4.50B	3.87B	3.91B	3.21B	3.49B	3.31B	4.52B
EPS Basic	7.30	6.76	0.14	5.73	5.16	2.79	3.84	2.40
EPS Diluted	7.28	6.74	0.14	5.71	5.14	2.78	3.82	2.32
Shares Outstanding	2.50B	2.53B	2.61B	2.53B	2.53B	2.53B	2.56B	2.59B
Diluted Shares Outstanding	2.51B	2.54B	2.55B	2.54B	2.54B	2.54B	2.58B	2.68B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.